Oral Monomethyl Fumarate Therapy Ameliorates Retinopathy in a Humanized Mouse Model of Sickle Cell Disease.

MLA

Promsote, Wanwisa, et al. “Oral Monomethyl Fumarate Therapy Ameliorates Retinopathy in a Humanized Mouse Model of Sickle Cell Disease.” Antioxidants & Redox Signaling, vol. 25, no. 17, Dec. 2016, pp. 921–35. EBSCOhost, https://doi.org/10.1089/ars.2016.6638.

APA

Promsote, W., Powell, F. L., Veean, S., Thounaojam, M., Markand, S., Saul, A., Gutsaeva, D., Bartoli, M., Smith, S. B., Ganapathy, V., & Martin, P. M. (2016). Oral Monomethyl Fumarate Therapy Ameliorates Retinopathy in a Humanized Mouse Model of Sickle Cell Disease. Antioxidants & Redox Signaling, 25(17), 921–935. https://doi.org/10.1089/ars.2016.6638

Chicago

Promsote, Wanwisa, Folami Lamoke Powell, Satyam Veean, Menaka Thounaojam, Shanu Markand, Alan Saul, Diana Gutsaeva, et al. 2016. “Oral Monomethyl Fumarate Therapy Ameliorates Retinopathy in a Humanized Mouse Model of Sickle Cell Disease.” Antioxidants & Redox Signaling 25 (17): 921–35. doi:10.1089/ars.2016.6638.